BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23427943)

  • 1. Simultaneous suppression of Src and signal transducer and activator of transcription 3 inhibits the growth of epithelial ovarian cancer cells.
    Lee SW; Yoo J; Lee SH; Kim D; Kim YM; Kim YT
    Eur J Obstet Gynecol Reprod Biol; 2013 Jul; 169(1):75-9. PubMed ID: 23427943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro.
    Tang YJ; Sun ZL; Wu WG; Xing J; He YF; Xin DM; Han P
    Genet Mol Res; 2015 Mar; 14(1):2450-60. PubMed ID: 25867391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer.
    Sheng WJ; Jiang H; Wu DL; Zheng JH
    Braz J Med Biol Res; 2013 Aug; 46(8):650-8. PubMed ID: 23969971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer.
    Chen L; Liang L; Yan X; Liu N; Gong L; Pan S; Lin F; Zhang Q; Zhao H; Zheng F
    Int J Gynecol Cancer; 2013 Feb; 23(2):256-63. PubMed ID: 23358177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cisplatin resistant effects of dihydrofolate reductase gene expression up-regulation in epithelial ovarian cancer].
    Li Z; Wang Q; Zhang W; Yang Z; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2015 Nov; 50(11):854-60. PubMed ID: 26887775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of XPG down-regulation gene expression towards the proliferation of epithelial ovarian cancer cells and its chemosensitivity to platinum].
    Zhang W; Wu FX; Wang Q; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):286-91. PubMed ID: 22781116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.
    Johnson FM; Saigal B; Tran H; Donato NJ
    Clin Cancer Res; 2007 Jul; 13(14):4233-44. PubMed ID: 17634553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (E)-2-methoxy-4-(3-(4-methoxyphenyl)prop-1-en-1-yl)phenol suppresses ovarian cancer cell growth via inhibition of ERK and STAT3.
    Zheng J; Son DJ; Lee HL; Lee HP; Kim TH; Joo JH; Ham YW; Kim WJ; Jung JK; Han SB; Hong JT
    Mol Carcinog; 2017 Sep; 56(9):2003-2013. PubMed ID: 28277616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation.
    Sankpal UT; Ingersoll SB; Ahmad S; Holloway RW; Bhat VB; Simecka JW; Daniel L; Kariali E; Vishwanatha JK; Basha R
    Tumour Biol; 2016 Oct; 37(10):14259-14269. PubMed ID: 27581819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth inhibition of human ovarian cancer cells by blocking STAT3 activation with small interfering RNA.
    Cai L; Zhang G; Tong X; You Q; An Y; Wang Y; Guo L; Wang T; Zhu D; Zheng J
    Eur J Obstet Gynecol Reprod Biol; 2010 Jan; 148(1):73-80. PubMed ID: 19880237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of STAT3 activation and expression in canine and human osteosarcoma.
    Fossey SL; Liao AT; McCleese JK; Bear MD; Lin J; Li PK; Kisseberth WC; London CA
    BMC Cancer; 2009 Mar; 9():81. PubMed ID: 19284568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of survivin siRNA on growth, apoptosis and chemosensitivity of ovarian cancer cells SKOV3/DDP].
    Zhang X; Li N; Wang YH; Huang Y; Xu NZ; Wu LY
    Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):174-7. PubMed ID: 19615253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer.
    Wang Y; Wang H; Song T; Zou Y; Jiang J; Fang L; Li P
    Mol Med Rep; 2015 Aug; 12(2):2211-6. PubMed ID: 25824616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding.
    Sen B; Saigal B; Parikh N; Gallick G; Johnson FM
    Cancer Res; 2009 Mar; 69(5):1958-65. PubMed ID: 19223541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The inhibitory effect of doxycycline on cisplatin-sensitive and -resistant epithelial ovarian cancer.
    Wu W; Yu LH; Ma B; Xu MJ
    PLoS One; 2014; 9(3):e89841. PubMed ID: 24598933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
    Ma JJ; Chen BL; Xin XY
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429.
    Guo Q; Lu L; Liao Y; Wang X; Zhang Y; Liu Y; Huang S; Sun H; Li Z; Zhao L
    Cell Death Dis; 2018 Jan; 8(1):e3178. PubMed ID: 29324735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Influence of human epidermal growth factor receptor-2 siRNA on chemosensitivity to cisplatin of human ovarian carcinoma cells: an in vitro experiment].
    Lu YM; Zhang SL; Meng LR; Zhao YY
    Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(13):909-13. PubMed ID: 18756958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer].
    Chen J; Wang Q; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Apr; 51(4):285-92. PubMed ID: 27116987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.
    Selvendiran K; Ahmed S; Dayton A; Kuppusamy ML; Rivera BK; Kálai T; Hideg K; Kuppusamy P
    Cancer Biol Ther; 2011 Nov; 12(9):837-45. PubMed ID: 21885917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.